Figure 2. Sensitivity of results expressed as percent change from the central point estimate of the benefits obtained for
the different end-points studied. (1) Use of upper and lower bound of the 95% of CRF; (2) use of central estimate of
alternative CRFs; (3) assuming some error in the baseline frequencies used; (4) use different monetary valuation range
and approach. ACS: American Cancer Society; CB: chronic bronchitis; CC: chronic cough; CVD: cardiovascular;
CRF: concentration response function; LRS: lower respiratory symptoms; Resp: respiratory; VOLY: value of life year;
WTP: willingness-to-pay. Reference for alternative CRFs: ¹Pope et al.(2002)^35;2Jerret et al.(2005)^30;3WHO (2004)^15;4
Medina et al.(2005)^12;5Le Tertre et al.(2002)^17;6 Abbey et al.(1995)^22;7Dockery et al.(1989)^23;8Dusseldorp et al.(1995)^24;9
Roemer et al.(1993)^25;10CAFE (2005)¹⁰.